https://european-biotechnology.net/wp-content/uploads/2026/04/FRJ_1631-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-29 14:00:092026-04-29 14:00:09Inside Servier’s new €200M venture fund
https://european-biotechnology.net/wp-content/uploads/2026/04/paris-bilal-fvADKM7vxBM-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-29 13:52:362026-04-29 13:52:36Chiesi in US$1.9bn deal to buy KalVista and its angioedema drug
https://european-biotechnology.net/wp-content/uploads/2026/04/andrej-lisakov-3ZC4pGRcszA-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-27 12:00:042026-04-27 12:00:04CureVac takes Moderna to court over mRNA vaccine patents
https://european-biotechnology.net/wp-content/uploads/2026/04/getty-images-X37jT1yreKs-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-23 15:57:592026-04-23 15:57:59Kurma Partners closes Biofund IV at €215M, giving European biotech a fresh specialist pool of capital
